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T-cell lymphoma is a heterogeneous group of diseases. Except for ALK positive anaplastic large cell lymphoma, T-cell lymphoma
responds to conventional chemotherapy unfavourably, and most patients carry poor prognosis. In recent years, eﬀorts have
been made to improve the outcome of T-cell lymphoma patients. Novel agents, high-dose therapy, and allogeneic stem cell
transplantation are studied, and various results are reported in literature. This paper looks into the prognostication and treatment
approach of diﬀerent entities of noncutaneous T-cell lymphoma and would focus on the latest updates in its management.
1.Introduction
T - c e l ll y m p h o m aa c c o u n t sf o r1 0t o1 5p e r c e n to fa l l
non-Hodgkin lymphomas worldwide. In the latest WHO
classiﬁcation of Tumours of Haematopoietic and Lymphoid
Tissues,therearealtogethernineteenmatureT-celllymphoid
malignancies [1]. All of them carry poor prognosis with the
notable exception of anaplastic lymphoma kinase (ALK)-
positive anaplastic large cell lymphoma. They in general
respond poorly to conventional chemotherapy with the
reported 5-year overall survival (OS) rate and event-free
survival (EFS) rate of 41% and 33%, respectively [2], which
compares unfavourably with B-cell lymphoid neoplasms [2–
4].
InternationalPrognosticIndex(IPI)wasoriginallydevel-
oped to prognosticate B-cell lymphoma patients. It has been
used in T-cell lymphoma patients, but its applicability in
them has been doubted [5]. Deﬁnitely, there is a need of a
reliable prognostic model to stratify this group of patients.
Various attempts were made to improve the dismal
outcome of T-cell lymphomas. These include diﬀerent
combinations of conventional chemotherapy, novel agents,
high-dose therapy, and allogeneic stem cell transplantation.
Despite all these advances, cyclophosphamide, doxorubicin,
vincristine, and prednisolone- (CHOP-) like therapy are still
the standard ﬁrst-line treatment.
This paper looks into the various prognostic markers
in T-cell lymphoma as well as the latest updates in its
management.
2. T-Cell Lymphomas: ClinicalCharacteristics
Among the nineteen subtypes of T-cell lymphomas,
angioimmunoblastic T-cell lymphoma, anaplastic large cell
lymphoma, and peripheral T-cell lymphoma not otherwise
speciﬁed (PTCL-NOS) are the most commonly seen. They
each accounts for 20% to 30% of all T-cell lymphomas [1].
The median age at presentation is between the ﬁfth and sixth
decade with a male predominance, with the exception of
ALK-positiveanaplasticlargecelllymphomawhichisusually
diagnosed in patients younger than 30 [1, 6].
All T-cell lymphomas behave aggressively except ALK-
positive anaplastic large cell lymphoma. They present at an
advanced stage, and almost all patients have high IPI scores.
A great majority of them had bone marrow and extranodal
involvement upon diagnosis. The reported 5-year overall
survival and progression-free survival ranged between 32%
to 49% and 18% to 36%, respectively [7]. It is important
to distinguish cases of ALK-positive anaplastic large cell
lymphoma in analysis of T-cell lymphomas because of its
exceptional good prognosis. The 5-year overall survival of
this group of patients reaches 80% [8, 9].2 Advances in Hematology
3.PrognosticMarkersinT-Cell Lymphoma
IPI has been the standard prognostic model for B-cell
lymphomas for years. It has been applied in T-cell coun-
terparts as well. It stratiﬁed anaplastic large cell lymphomas
(both ALK positive and ALK negative) and PTCL-NOS into
two prognostic groups. The overall survival at 5 years is
signiﬁcantly better in patients withIPI scoresless than 1 than
those with scores higher than 4 (50% to 90% versus 11% to
33%) in these two types of T-cell lymphomas [7]. However,
IPI cannot diﬀerentiate high-risk patients in some rare
subtypes of T-cell lymphomas like enteropathy-associated T-
cell lymphoma, hepatosplenic T-cell lymphoma, and adult
T-cell leukemia/lymphoma. Patients with these lymphomas
fared poorly even with a low IPI score. IPI also has lim-
ited applicability in angioimmunoblastic T-cell lymphoma
because most patients have high IPI scores at presentation
[5, 10]. A prognostic model was speciﬁcally developed for
PTCL-NOS, the Prognostic Index for PTCL-U, (PIT). It
consists of age, performance status, lactate dehydrogenase
level, and bone marrow involvement and divides patients
into fourgroupsdepending onthenumber ofadversefactors
they have [11]. It showed a superior predictive power of
survival when compared with IPI in this study (log-rank
66.79 versus 55.94). However, even for patients with no
adverse factor (i.e., group 1), the 5-year overall survival
rate was only 62%. Therefore, it is apparent that a great
majority of T-cell lymphoma patients, with the exception of
ALK-positive anaplastic large cell lymphoma, have a dismal
prognosis irrespective of their prognostic scores.
4. Advances in Management of
T-Cell Lymphomas
Conventional CHOP-like chemotherapy yields poor
response in T-cell lymphomas excluding ALK-positive
anaplastic large cell lymphoma. The reported complete
remission rate with CHOP-like regimens was less than
50%, and the 5-year overall survival ranged from 26% to
45% [4, 12, 13]. This result is certainly inferior to B-cell
lymphomas even prior to the era of Rituximab. The use of
anthracycline does not bring any improvement in outcome
either [4, 7]. A recent trial reported that the addition of
etoposide to CHOP improved event-free survival in young
patients with ALK-positive anaplastic large cell lymphomas
(event-freesurvivalat3years91.2%versus57.1%,P = .012),
but the overall survival was not signiﬁcantly diﬀerent. There
was a trend towards a better event-free survival in the
remaining T-cell lymphoma patients, but it did not reach
statistical signiﬁcance (3-year event-free survival 60.7%
versus 48.3%, P = .057) [14].
5. IntensiveChemotherapy Regimens
Intensive chemotherapy did not produce improvement
in treatment results in this group of patients. GELA
(Groupe d’Etudes des Lymphomes) showed that intensive
ACVBP regimen (doxorubicin, cyclophosphamide, vinde-
sine, bleomycin, and prednisolone) was better than CHOP
i nt e r m so fo v e r a l ls u r v i v a la n de v e n t - f r e es u r v i v a l( 5 - y e a r
overall survival rates 46% versus 38% (P = .036) and
5-year event-free survival 39% versus 29% (P = .007)).
However, only 15% of the total 635 patients had T-cell
lymphomas, and the outcome of this subgroup of patients
was not reported separately [16]. In studies that only
included T-cell lymphoma patients, none of them showed
that dose-intense therapy improved outcome. In fact, a
subsequent report by GELA group showed that ACVBP
was not superior to conventional CHOP in treatment of
angioimmunoblastic T-cell lymphoma patients [5]. MD
Anderson group compared CHOP with intensive regimens
(hyper-CHOP, hyper-CVAD, and alternating triple therapy)
in 135 T-cell lymphoma patients (including 40 anaplastic
large cell lymphoma patients). There was no signiﬁcant
diﬀe r e n c ei no v e r a l ls u r v i v a la sw e l la sc o m p l e t er e m i s s i o n
rates between the two groups. Similar results were obtained
when the patients with anaplastic large cell lymphoma were
excluded from analysis [15]. Table 1 summarized the results
of these studies. In conclusion, there was so far no regimen
shown to be superior to CHOP in the literature.
6. High-DoseTherapyandAutologousStemCell
Transplantation
Studies evaluating the role of autologous stem cell trans-
plantation in treatment of T-cell lymphomas showed con-
ﬂicting results. Autologous stem cell transplantation failed to
improve survival for angioimmunoblastic T-cell lymphoma
patients in a GELA study. However, the disease status of
patients at transplantation was not known [5]. The same
group reported another study comparing the outcome of
aggressivelymphomaswitheitherautologousstemcelltrans-
plantation or chemotherapy consolidation. They received
induction chemotherapy followed by consolidation with
either autologous stem cell transplantation or chemotherapy
if they achieved complete remission. They did not ﬁnd any
signiﬁcant diﬀerence in remission rates and survival in the
subgroup of patients with nonanaplastic T-cell lymphoma
[17]. A recent study in Germany also found that front-
line high-dose therapy (Mega CHOP plus etoposide) with
autologous stem cell transplantation had complete remission
rate of less than 50% in patients with nonanaplastic T-
cell lymphomas [18]. The overall survival and event-free
survival at 3 years were 25.9% (95% C.I. 10.4%–41.4%)
and 44.5% (95% C.I. 26.5%–62.5%), respectively, which was
signiﬁcantly worse than B-cell counterparts. Moreover, in
33 T-cell lymphoma patients enrolled in this study, only 22
patients (66.7%) were able to undergo autologous stem cell
transplantation as per protocol. The majority of early drop-
outs was due to disease progression during therapy.
On the contrary, some better results were reported
when autologous stem cell transplantation was done in
ﬁrst complete remission. A retrospective study in Spain
showed the 5-year overall survival rate and progression-
free survival rate of 68% and 63%, respectively, whenAdvances in Hematology 3
Table 1: Summary of various treatment results of T-cell lymphomas.
Author Year No. of
patients ALK + ve ALCL Regimens CR ORR OS EFS Ref
Lopez-Guillermo
et al. 1998 174 30 (ALK status not
known)
120 CHOP 54 not
speciﬁed 49% 64% 38%
(at 4 years) Not available [4]
Armitage et al. 1989 134 Not known 80 CHOP-like 54
not speciﬁed 50% Not
available
45%
(at 4 years) Not available [12]
Rudiger et al. 2002 129 0 90 CHOP-like 39
not speciﬁed
Not
available
Not
available
26%
(at 5 years)
20%
(at 5 years)
[13]
Schmitz et al. 2010 343 78 122 CHOP 221
CHOEP
Not
available
Not
available
53.9%–67.5%
(at 3 years)
41.1%–50.0%
(at 3 years)
[14]
Mourad et al. 2008 157 0
ACVBP +
CHOP-like
regimens
46% Not
available
33%
(at 5 years)
29%
(at 5 years)
[5]
Escalon et al. 2005 24 0 CHOP 58% Not
available
43%
(at 3 years) Not available [15]
Escalon et al. 2005 52 0 HyperCVAD like 59% Not
available
49%
(at 3 years) Not available [15]
autologous stem cell transplantation was done in ﬁrst
complete remission [19]. However, 31% of the patients
were anaplastic large cell lymphomas, and the status of
ALK expression was not known. Even when anaplastic large
cell lymphomas were excluded from analysis, the overall
survival and progression-free survival rate at 5 years were
61% and 55%, respectively, which is remarkably better than
the results obtained with conventional chemotherapy. The
same group reported a superior outcome with autologous
stem cell transplantation as consolidation for patients with
peripheral T-cell lymphoma (excluding cases with ALK-
positive anaplastic large cell lymphoma), who achieved a
complete or partial remission after induction chemotherapy
in a prospective trial [20]. The complete remission rate
was 89% after autologous stem cell transplantation, and the
overall survival and progression-free survival were 73% and
53%, respectively, at 3 years. In other prospective trials of 83
patients with T-cell lymphomas, autologous stem cell trans-
plantation was done in 55 of enrolled patients who achieved
at least a partial remission after induction chemotherapy.
The complete remission rate after stem cell transplantation
w a s7 8 % ,a n dt h eo v e r a l ls u r v i v a la t3y e a r sw a s7 1 %[ 21].
In two prospective studies done by an Italian group, 46
(74%) of 62 enrolled patients underwent autologous stem
cell transplantation as consolidation after they achieved
complete remission with induction chemotherapy. After a
medianfollowupof76months,theestimatedoverallsurvival
and event-free survival at 12 years were 34% and 30%,
respectively. When patients with ALK-positive anaplastic
large cell lymphomas are excluded, the overall and event-free
survival at 12 years dropped to 21% and 18%, respectively
[22].
Based on these retrospective and prospective studies, it
seems that autologous stem cell transplantation is beneﬁcial
if it is done in ﬁrst complete remission and when the
disease is chemosensitive. Unfortunately, it is apparent that
a signiﬁcant number of patients have progression early in
disease course such that autologous stem cell transplantation
is not feasible at all. It is therefore the challenge how to
improve the complete remission rate in nonanaplastic T-cell
lymphomas and how to salvage patients who do not respond
to frontline induction chemotherapy.
7. Novel Agents
Alemtuzumab is a humanized monoclonal anti-CD 52
antibody. CD 52 is expressed by both T-cells and B-cells.
It was shown to produce superior remission rate (complete
remission of 71%) when alemtuzumab was combined with
CHOP as frontline treatment in a group of 24 patients with
peripheral T-cell lymphomas (none of the them were ALK-
positive anaplastic large cell lymphoma) [23]. The median
duration of complete remission was 11 months. However,
there was a high incidence of infectious complications
despite anti-infective prophylaxis. The marked immunosup-
pression associated with alemtuzumab is a major issue that
needs to be addressed when this antibody is administered.
Gemcitabine, a pyrimidine analogue, was studied in
peripheralT-celllymphomaseitherassingleagent[24,25]or
combinationtreatment[26, 27] in both frontline and salvage
setting. An overall response rate from 51% to 77% was
achieved. It was well tolerated with mainly haematological
toxicity reported. However, only a small number of patients
were enrolled in each of these studies, and well-designed
randomized controlled trials are needed before its role is
deﬁned in T-cell lymphoma management.
Pralatrexate is a new folate antagonist which is struc-
turally similar to methotrexte but with greater aﬃnity for
one carbon-reduced folate carrier, and hence it is selectively
accumulatedinmalignantcells.Bothinvitroandinvivodata
demonstrated superior eﬃcacy of pralatrexate compared
with methotrexate [28, 29]. It was demonstrated to have
activity in peripheral T-cell lymphomas with an overall
response rate of 54% achieved in a phase II study [30]. In the
largest prospective study of relapsed or refractory peripheral
T-cell lymphomas, Pralatrexate in Relapsed or Refractory4 Advances in Hematology
Peripheral T-cell Lymphoma (PROPEL), an overall response
rate of 29% was seen in 109 heavily pretreated patients, and
the median duration of response was 9.4 months [31]. The
main toxicity reported was mucositis and cytopenia, both of
which were manageable. This result is impressive and led to
its approval by Food and Drug Administration for treatment
of relapsed or refractory peripheral T-cell lymphoma.
Histone deacetylase inhibitors are also shown to have
activities in T-cell lymphomas. Vorinostat and romidepsin
are approved by FDA for treatment of cutaneous T-cell
lymphoma. A phase II study of romidepsin in 48 relapsed
or refractory peripheral T-cell lymphoma patients found
an overall response rate of 31% and a median duration of
response of 9 months [32]. Ongoing studies are underway
to evaluate the activity of this group of agents in peripheral
T-cell lymphomas.
Apart from the above agents, there are some early
results of novel agents such as mTOR (mammalian target
of rapamycin) inhibitors [33], monoclonal antibodies anti-
CD30 [34], and anti-CD4 [35] that they may be active
in T-cell lymphomas. In addition, proteosome inhibitor
bortezomib [36], purine analogue clofarabine [37], and
lenalidomide [38] are also reported to be useful in T-
cell lymphomas. However, more clinical trials on them
are necessary before their eﬃcacy in T-cell lymphoma
management is determined.
8. Allogeneic Stem CellTransplantation
There are encouraging results of allogeneic stem cell trans-
plantation in management of peripheral T-cell lymphoma.
European Group for Blood and Marrow Transplantation
reported a retrospective study of 45 angioimmunoblastic T-
cell lymphoma patients who received at least two lines of
chemotherapy prior to study entry. They showed that the 3-
year overall survival rate and progression-free survival rate
of these heavily pretreated patients were 64% and 54%,
respectively [39]. The cumulative incidence of relapse at
3 years was only 20%, and the cumulative incidence of
nonrelapse mortality at 12 months after transplantation was
25%. The development of chronic graft-versus-host disease
was associated with a lower incidence of relapse, but the
diﬀerence did not reach statistical signiﬁcance. Patients with
chemosensitive diseases had a signiﬁcantly better outcome
(overall survival at 3 years 81% versus 64%, P = .002;
progression-free survival at 3 years 66% versus 53%, P =
.004). Another study from France which included 77 T-
cell lymphoma patients undergoing allogeneic stem cell
transplantation showed that the 5-year overall survival and
event-free survival rate were 57% and 53%, respectively [40].
Better overall and event-free survival at 5 years was observed
in those transplanted in complete or partial remission than
patients with chemoresistant diseases (5-year overall survival
69% versus 29%; 5-year event-free survival 64% versus
27%, P = .0002). Two patients in this study relapsed and
achieved a second complete remission after donor lympho-
cyte infusion. Both of them had remained in remission for at
least two years after donor lymphocyte infusion. In addition,
26% of patients in this study underwent reduced intensity
conditioning (RIC) allogeneic stem cell transplantation, and
they showed a trend of longer event-free survival and less
transplant-related mortality in univariate analysis (P =
.108 and .107 resp.). This suggested a signiﬁcant role of
graft-versus-lymphoma eﬀect in T-cell lymphomas. In fact,
RIC allogeneic stem cell transplantation is an attractive
option, particularly in patients who are heavily pretreated,
aged, or with comorbidities. Some favourable results of RIC
allogeneic stem cell transplantation in T-cell lymphomas
are reported. In a prospective trial in Italy, 17 patients
with peripheral T-cell lymphomas underwent RIC allogeneic
transplantation. The overall survival and progression-free
survival at 3 years were 81% and 64%, respectively, while
the nonrelapse mortality was only 6% at 2 years [41].
Another recently published study done in United States
showed a slightly inferior outcome with the overall survival
and progression-free survival at 3 years of 59% and 53%,
respectively, while the nonrelapse mortality at 3 years was
19% [42]. However, the median age of patients enrolled
in this study was 57 (compared with median age of 41 in
the former study), and a larger proportion of patients had
chemoresistant disease at transplantation. Notwithstanding,
based on the above results, RIC allogeneic transplantation
appears to be a feasible and eﬀective treatment option with
acceptable toxicity for T-cell lymphomas.
9. Conclusion
T-cell lymphomas are a heterogeneous group of diseases
but are uniformly aggressive and respond poorly to our
conventional chemotherapy, with the notable exception of
ALK-positiveanaplasticlargecelllymphoma.Someadvances
were made in its treatment in recent years, and some novel
agents show early promising results.
Allogeneic stem cell transplantation should be consid-
ered in patients with poor-risk disease, and RIC extended
this option to the older, more heavily pretreated patients.
It is hoped that with the availability of novel agents, we are
able to bring more patients into complete remission before
transplantation and improve their outcome.
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